U.S., April 23 -- ClinicalTrials.gov registry received information related to the study (NCT07543731) titled 'A Real-World Study of Long-Term Adherence and Persistence to Inclisiran, Evolocumab, and Alirocumab' on April 14.
Brief Summary: This study aims to evaluate the long-term adherence and persistence to inclisiran and anti-proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAbs) in real-world clinical practice.
Study Start Date: April 21
Study Type: OBSERVATIONAL
Condition:
Cardiovascular Diseases
Atherosclerotic Cardiovascular Disease
Hypercholesterolemia, Familial
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Novartis Pharmaceuticals
Published by HT Digital Content Services with permission from Hea...